This acquisition expands Sino-American Crown Division’s pre-clinical in vitro service platform, adding high-content imaging and advanced tumor organoid analysis to three-dimensional tumor immunological drug detection
May 06, 2021 08:32 AM Eastern Daylight Time
San Diego, California--( BUSINESS WIRE ) --( BUSINESS WIRE )--Zhongmei Guanke Biotechnology Co., Ltd. (Zhongmei Guanke) is a leading preclinical translational medicine platform, which is a subsidiary of JSR Life Sciences. Assist customers in accelerating new drug research and development projects. The company's acquisition of OcellO BV is a personally owned contract outsourcing service organization located in the Netherlands. Through this acquisition, Sino-American Crown will expand its in vitro service platform and integrate OcellO's high-content imaging technology into Crown's in vitro and in vivo screening platform and immune efficacy evaluation services. Financial terms have not yet been made public.
"China-US Crown Technology and OcellO firmly believe that the key to improving the success of clinical research is to use more patient-related models and methods to improve the reliability of data in the early drug development process." said Dr. Armin Spura, CEO of China-US Crown Technology. This acquisition combines the advantages of the two companies and strengthens our in vitro service platform to provide customers with better drug efficacy evaluation. Improve the predictability and clinical significance of the drug development stage from in vitro to in vivo.
The acquisition also makes Guanke the only authorized organization in the world to provide customers with professional Hubrecht organoid technology (HUB) for drug development projects. According to the terms of the agreement, Dr. Leo Price, Chief Executive Officer and Chief Science Officer of OcellO, will join Crown Division as the senior vice president of In Vitro, and will be responsible for leading the research and development of the In Vitro Platform in the United States and Europe.
Dr. Price said: "I am very happy to join Crown Technology and help Crown Technology's in vitro platform grow. We will jointly inherit the spirit of innovation and dedication, and serve our customers wholeheartedly to meet their complex needs in the early stages of drug development. The expertise is particularly suitable for large-scale disease-related screening, enabling our customers to evaluate multiple drug combinations in a fast, scientifically rigorous, and cost-effective manner."
About Sino- US Crown Biotechnology Co., Ltd. (CrownBio) is a subsidiary of JSR Life Sciences, a global drug discovery and development company that provides a translational medicine platform for the advancement of tumor and inflammation research. Sino-American Crown Technology has a large number of related model libraries and prediction tool combinations, and can provide customers with excellent clinical drug candidate screening services. For more information, please visit: www.crownbio.com
About OcellO BV
OcellO is an industry leader in providing compound testing services using advanced cancer, inflammation and polycystic kidney organ-type human tissues. Automated 3D cell culture and high-content 3D imaging and analysis provide a solid and scalable sample analysis platform without compromising biological complexity. Oncology drug development services include organoids, humanized organoids and humanized tumor xenograft models representing most solid tumor models and combining different immune systems.
###
Disclaimer: The original version of this announcement is the officially authorized version. The translation is only for the convenience of understanding, please refer to the original text. The original text is the only legally valid version.
Media Inquiries
Mike Beyer
Sam Brown Inc.
+1 312-961-2502
mikebeyer@sambrown.com
Company Inquiries
Gavin Cooper
Crown Bioscience Inc.
+1 518-488-9062
gavin.cooper@crownbio.com
